The global inflammatory bowel disease drug market is anticipated to grow at a considerable CAGR of around 4.7% during the forecast period. Pharmaceutical companies are working on developing new therapies and drugs for the treatment of Inflammatory bowel disease. At present, clinical trials are helping to introduce treatment for prolonged inflammatory bowel disease. In inflammatory bowel disease, symptoms occur at definite intervals even if medication is given to the affected person. They are a chronic disease that is cured by treating their symptoms and not the actual disease. Most of the people who are affected by ulcerative colitis undergo surgery. There are complications in surgery as well. The colon and rectum area is removed in surgical procedure and the small intestine performs the function of the colon. This develops complications inpatient.
Browse the full report description of “Global Inflammatory bowel disease drugs Market Size, Share & Trends Analysis Report by Type (Crohn’s disease and Ulcerative colitis), By Drug (Aminosalicylates, Corticosteroids, TNF Inhibitors, IL Inhibitors, Anti-integrin, JAK Inhibitors, and Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/inflammatory-bowel-disease-drugs-market
There is a need for concrete therapy for these chronic disease and developments are going on. For instance, in May 2021, a new study which was published in Nature Communications show that good bacteria which are present in the GI tract of a healthy human can be used to treat the affected areas of the stomach where there are complications of IBD. Gusto global which is a biotech firm developed this consortia of bacteria which is known as GUT-103 and GUT-108. GUT 103 has bacteria that feed each other and has around 17 strains. In GUT-108, there are around 11 human isolated. This combination lets bacteria stay in the colon part of the digestive tract. Bacteria stay in the colon for a long period and the combination does not let them pass through the system quickly.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Drug
o By Distribution channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Abbvie Inc., Biogen Inc., Johnson and Johnson Services, Inc., Amgen, Inc., UCB Biopharma SRL, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Inflammatory Bowel Disease Drugs Market Report by Segment
By type
By Drug
By Distribution Channel
Global Inflammatory Bowel Disease Drugs Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/inflammatory-bowel-disease-drugs-market